Within this concepTT we want to convince a company to license our biomarker by validating the Rab27B score on a large patient group with 10 years clinical outcome data. This biomarker could be marketed as a unique prognostic biomarker to identify poor prognosis hormone-sensitive breast tumors that should receive adjuvant cytotoxic therapy